Evrys Bio - formerly dba Forge Life Sciences LLC - is a pre-clincial biotechnology company developing anti-viral treatments. Anchored in technology licensed from Princeton University, Evrys Bio is developing anti-viral therapies based on sirtuin modulators. Traditional antivirals are direct-acting antivirals targeting a protein of a specific virus limiting their effectiveness against more than one virus type. Where immuno-oncology drugs engage the patients immune system to fight cancer, Evrys Bio antivirals engage the cells intrinsic immunity to defend against infection. The vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broad-spectrum treatment options. If successful, the approach could potentially transform the practice of medicine - addressing the infectious disease condition as opposed to targeting a specific virus-type. The physician would be prescribing a safe, broad-spectrum antiviral, without the risk of acquired drug-resistance, based on symptom presentation, and prior to diagnostic confirmation of infecting virus-type.
